Therapeutic reactivation of mutant p53 protein by quinazoline derivatives

Investigational New Drugs

Volumn 30, Issue 5, 2012, Pages 2035-2045

  Sutherland, Hamish S ^a   Hwang, In Young ^a   Marshall, Elaine S ^a   Lindsay, Brent S ^a   Denny, William A ^a   Gilchrist, Catherine ^a   Joseph, Wayne R ^a   Greenhalgh, Debra ^a   Richardson, Emma ^a   Kestell, Philip ^a   Ding, Angela ^a   Baguley, Bruce C ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Cell cycle arrest; Flow cytometry; Quinazoline synthesis; TP53 mutation; Tumour growth delay

Indexed keywords

4 (3 DIMETHYLAMINOPROPYLAMINO) 2 (4 METHOXYSTYRYL)QUINAZOLINE; AMSACRINE; CYCLIN DEPENDENT KINASE INHIBITOR 1; DNA; DOXORUBICIN; NUTLIN 3; PACLITAXEL; PROTEIN P53; QUINAZOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER RADIOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA BINDING; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENE MUTATION; HUMAN; HUMAN CELL; IC 50; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MELANOMA; MOUSE; MUTANT; NONHUMAN; OVARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR CELL LINE; TUMOR XENOGRAFT;

ANIMALS; CELL CYCLE; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; HUMANS; MICE; MUTANT PROTEINS; MUTATION; QUINAZOLINES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84867857139     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-011-9744-z     Document Type: Article

References (31)

1. Lane DP (1992) Cancer. p53, guardian of the genome. Nature 358:15-16
2. Levine AJ (1997) p53, the cellular gatekeeper for growth and division. Cell 88:323-331
3. Sengupta S, Harris CC (2005) p53: traffic cop at the crossroads of DNA repair and recombination. Nat Rev Mol Cell Biol 6:44-55
4. Han J, Goldstein LA, Hou W, Gastman BR, Rabinowich H (2010) Regulation of mitochondrial apoptotic events by p53-mediated disruption of complexes between antiapoptotic Bcl-2 members and Bim. J Biol Chem 285:22473-22483
5. Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, Cordon-Cardo C, Lowe SW (2007) Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445:656-660
6. Cadwell C, Zambetti GP (2001) The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth. Gene 277:15-30
7. Cheok CF, Verma CS, Baselga J, Lane DP (2010) Translating p53 into the clinic. Nature Rev Clin Oncol 8:25-37
8. Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP (2009) Awakening guardian angels: drugging the p53 pathway. Nature Rev Cancer 9:862-873
9. Foster BA, Coffey HA, Morin MJ, Rastinejad F (1999) Pharmacological rescue of mutant p53 conformation and function. Science 286:2507-2510
10. Tang X, Zhu Y, Han L, Kim AL, Kopelovich L, Bickers DR, Athar M (2007) CP-31398 restores mutant p53 tumor suppressor function and inhibits UVB-induced skin carcinogenesis in mice. J Clin Invest 117:3753-3764
11. El Deiry WS (2007) Targeting mutant p53 shows promise for sunscreens and skin cancer. J Clin Invest 117:3658-3660
12. Rippin TM, Bykov VJ, Freund SM, Selivanova G, Wiman KG, Fersht AR (2002) Characterization of the p53-rescue drug CP-31398 in vitro and in living cells. Oncogene 21:2119-2129
13. Wischhusen J, Naumann U, Ohgaki H, Rastinejad F, Weller M (2003) CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death. Oncogene 22:8233-8245
14. Ram VJ, Farhanullah, Tripathi BK, Srivastava AK (2003) Synthesis and antihyperglycemic activity of suitably functionalized 3H-quinazolin-4-ones. Bioorg Med Chem 11:2439-2444
15. Coffey HA, Connell RD, Foster BA, Rastinejad F. Methods and compositions using hydrophobic group- and cationic group-containing compounds for restoring conformational stability of a protein of the p53 family. (PCT Int. Appl.CODEN: PIXXD2 WO 2000032175 A2 20000608 CAN 133:26844 AN 2000:383903 CAPLUS), 1-76. 2000
16. Parmar J, Marshall ES, Charters GA, Holdaway KM, Shelling AN, Baguley BC (2000) Radiation-induced cell cycle delays and p53 status of early passage melanoma cell lines. Oncol Res 12:149-155
17. Baguley BC, Marshall ES, Whittaker JR, Dotchin MC, Nixon J, McCrystal MR, Finlay GJ, Matthews JH, Holdaway KM, van Zijl P (1995) Resistance mechanisms determining the in vitro sensitivity to paclitaxel of tumour cells cultured from patients with ovarian cancer. Eur J Cancer 31A:230-237
18. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, Double JA, Everitt J, Farningham DA, Glennie MJ, Kelland LR, Robinson V, Stratford IJ, Tozer GM, Watson S, Wedge SR, Eccles SA (2010) Guidelines for the welfare and use of animals in cancer research. Br J Cancer 102:1555-1577
19. Basse B, Baguley BC, Marshall ES, Joseph WR, van Brunt B, Wake GC, Wall DJN (2004) Modelling cell death in human tumour cell lines exposed to the anticancer drug paclitaxel. J Math Biol 49:329-357
20. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu EA (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303:844-848
21. Baguley BC, Denny WA, Atwell GJ, Cain BF (1981) Potential antitumor agents. 34. Quantitative relationships between DNA binding and molecular structure for 9-anilinoacridines substituted in the anilino ring. J Med Chem 24:170-177
22. Denny WA, Baguley BC (1994) New anticancer acridines. In: Neidle S, Waring MJ (eds) Molecular aspects of anticancer drug-DNA interaction. London, pp 270-311
23. Nelson EM, Tewey K, Liu LF (1984) Mechanism of antitumor drug action: poisoning of mammalian DNA topoisomerase II on DNA by 4′-(9- acridinylamino)-methanesulfon-m-anisidide. Proc Natl Acad Sci U S A 81:1361-1365
24. Finlay GJ, Baguley BC, Snow K, Judd W (1990) Multiple patterns of resistance of human leukemia cell sublines to amsacrine analogues. J Natl Cancer Inst 82:662-667
25. Drummond CJ, Finlay GJ, Broome L, Marshall ES, Richardson E, Baguley BC (2010) Action of SN 28049, a new DNA binding topoisomerase II-directed antitumour drug: comparison with doxorubicin and etoposide. Invest New Drugs in press
26. Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K, Guldberg P, Sehested M, Nesland JM, Lukas C, Orntoft T, Lukas J, Bartek J (2005) DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434:864-870
27. Baguley BC (1991) DNA intercalating anti-tumour agents. Anticancer Drug Des 6:1-35
28. Sasaki M, Nie L, Maki CG (2007) MDM2 binding induces a conformational change in p53 that is opposed by heat-shock protein 90 and precedes p53 proteasomal degradation. J Biol Chem 282:14626-14634
29. Xu J, Timares L, Heilpern C, Weng Z, Li C, Xu H, Pressey JG, Elmets CA, Kopelovich L, Athar M (2010) Targeting wild-type and mutant p53 with small molecule CP-31398 blocks the growth of rhabdomyosarcoma by inducing reactive oxygen species-dependent apoptosis. Cancer Res 70:6566-6576
30. McLure KG, Lee PW (1998) How p53 binds DNA as a tetramer. EMBO J 17:3342-3350
31. Kitayner M, Rozenberg H, Kessler N, Rabinovich D, Shaulov L, Haran TE, Shakked Z (2006) Structural basis of DNA recognition by p53 tetramers. Mol Cell 22:741-753